loader2
Partner With Us NRI

Ipca Laboratories Ltd share Price Today

Company details

1,291.30
1,310.90
675.45
1,374.60
6M Return 18.97%
1Y Return 89.66%
Mkt Cap.(Cr) 32,954.88
Volume 94,725
Div Yield 0.31%
OI
-
OI Chg %
-
Volume 94,725

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500
Technical Outlook
    Nifty Pharma index has been in corrective phase since October 2021 undergoing significant price/time correction. Over past couple of weeks index has witnessed renewed buying interest and formed potential Bullish Morning star reversal pattern on Monthly time frame. We expect sector to outperform in coming months
     
    Ipca Laboratories share price offers favourable risk-reward setup ahead of its quarterly earnings  as it is poised near 80% retracement of post COVID rally (600-1383)
     
    Key observations that support our bullish stance:
    Share price formed potential bullish reversal candlestick pattern on monthly chart at key support of ₹770  as it is sustaining above previous month high for first time in six months
     
    In the month of March, share price bounced from lower band of key trendline connecting major swing lows over past one year
     
    We expect share price to rally towards ₹950 over next few months as it is monthly highs of October and November 2022 and breakdown level in June 2022
Fundamental Outlook
    Ipca is a pharma company manufacturing over 350 formulations and 80 APIs. Major therapeutic segments include pain management, cardiovascular and anti-diabetics, anti-infectives, anti-malarials, which together account for 75% of revenues.
     
    According to IQVIA, MAT sales of IPCA for Q4FY23 grew ~20% YoY , whereas IPM grew 15% for the same.

     We expect IPCA revenue to grow at ~10% CAGR (FY23E-25E) on the back of Incremental growth in other therapies (excluding malaria), especially non-communicable diseases like pain management, cardio-diabetology.

     Sustained traction from branded and generics exports sales with a revival in the EU likely to mitigate the US void. Better offtake and market gains in export of Sartan APIs remains key monitorable going forward .On this basis, we expect EBITDA of IPCA to grow at 26% CAGR (FY23E-25E)

     We expect commissioning of Devas plant and additional capacities from Ratlam plant can have positive implications.

     Ipca remains a decent player with a judicious mix of strong domestic franchise and a spread-out exports model with healthy balance sheet. That said, we believe progress on the margins front is likely to weigh on sentiments

Click here for full recommendation

Research view on more stocks

Pharmaceuticals company Ipca Laboratories announced Q3FY24 & 9MFY24 results:

Q3FY24 Financial Highlights:

  • Standalone Net Total Income increased by 4% to Rs 1,523.72 crore.
  • Consolidated Net Total Income surged by 32% to Rs 2,075.31 crore.
  • Indian formulations income grew by 11% to Rs 779.61 crore.
  • Exports Income rose by 1% to Rs 640.34 crore.
  • Standalone EBITDA margin (before forex gain/loss and other income) stood at 18.55% in Q3FY24, compared to 15.77% in Q3FY23.
  • Consolidated EBITDA margin (before forex gain/loss, other income, and exceptional items) stood at 16.12% in Q3FY24, compared to 15.00% in Q3FY23.
  • Standalone Net Profit increased by 19% to Rs 136.94 crore.
  • Consolidated Net Profit surged by 67% to Rs 179.88 crore.

9MFY24 Financial Highlights:

  • Standalone Net Total Income grew by 6% to Rs 4,752.03 crore.
  • Consolidated Net Total Income increased by 20% to Rs 5,777.88 crore.
  • Indian formulations income rose by 12% to Rs 2,407.33 crore.
  • Exports Income increased by 1% to Rs 1,976.32 crore.
  • Standalone EBITDA margin (before forex gain/loss, other income, and Unichem acquisition cost) stood at 19.55% in 9MFY24, compared to 17.63% in 9MFY23.
  • Consolidated EBITDA margin (before forex gain/loss, other income, Unichem acquisition cost, and exceptional items) stood at 17.34% in 9MFY24, compared to 16.64% in 9MFY23.
  • Standalone Net Profit grew by 11% to Rs 465.65 crore.
  • Consolidated Net Profit increased by 24% to Rs 487.76 crore.

Result PDF

View Other Company Results

Ipca Laboratories Ltd shares SWOT Analysis

Strengths (7)

  • Growth in Net Profit with increasing Profit Margin (QoQ)
  • Company with Low Debt
  • Increasing Revenue every quarter for the past 3 quarters

Weakness (6)

  • MFs decreased their shareholding last quarter
  • Inefficient use of capital to generate profits - RoCE declining in the last 2 years
  • Inefficient use of shareholder funds - ROE declining in the last 2 years

Opportunity (0)

Data not found

Threats (1)

  • High PE (PE > 40)

Resistance and support

R1 1,316.1
R2 1,334.5
R3 1,350.0
Pivot

1,300.67

S1 1,282.3
S2 1,266.8
S3 1,248.4
EMA SMA
1,305.3
1,278.6
1,220.1
1,125.1
1,312.0
1,276.7
1,215.8
1,098.7
Delivery and volume
CLIENT NAME DEAL TYPE ACTION DATE AVG. PRICE QUANTITY EXCHANGE
ISHARES CORE MSCI EMERGING MARKETS ETF Block Purchase 2022-11-14 867.55 158841 NSE
ISHARES CORE EMERGING MARKETS MAURITIUS CO Block Sell 2022-11-14 867.55 158841 NSE
ISHARES CORE MSCI EMERGING MARKETS ETF Block Purchase 2022-11-03 927.15 158842 NSE
Name Category Shares
Usha M Chandurkar PROMOTER 3.27%
Premchand Godha PROMOTER 2.29%
Usha Premchand Godha PROMOTER 0.95%
Sameer M Chandurkar PROMOTER 0.79%
Pranay Godha PROMOTER 0.67%
Prashant Godha PROMOTER 0.62%
Kaygee Investments Private Limited PROMOTER 21.47%
Kaygee Laboratories Private Limited PROMOTER 6.61%
Chandurkar Investments Private Limited PROMOTER 5.5%
Paschim Chemicals Pvt Ltd PROMOTER 4.01%

OUR RESEARCH VIEW

Investment recommendation
Call Date
20 Apr 2023
Entry Price 815.00
Target Price 940.00
Duration
3 Month

FINANCIALS

Sales
Operating Profit
Profit after Tax
Equity
Reserves and Surplus
Debt
Sales
Operating Profit
Profit after Tax
PE
Debt/Equity
P BV

Ipca Laboratories Ltd Stocks COMPARISON

Financials( in Cr) Ipca Laboratories Ltd Sun Pharmaceuticals Industries Ltd Cipla Ltd Divis Laboratories Ltd Zydus Lifesciences Ltd
Price 1,298.95 1,472.45 1,478.05 4,284.40 1,065.35
% Change 0.09 -0.96 -0.57 3.93 -0.99
Mcap Cr 32,954.88 353,290.08 119,332.88 113,737.54 107,199.14
Revenue TTM Cr 6,244.32 43,885.68 15,790.60 7,767.51 17,237.40
Net Profit TTM Cr 491.93 8,560.84 2,513.47 1,823.38 1,997.30
PE TTM 64.37 35.64 28.16 79.13 28.08
1 Year Return 89.66 54.64 57.57 26.64 111.40
ROCE 11.59 16.79 14.76 19.30 16.25
ROE 8.70 16.46 10.66 14.89 14.05
INSIDER & INSTITUTIONAL ACTIVITY

Equity Capital: 5,842.02 Cr FV: 1.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 29,248.28 -22,040.96
LAST 3M 102,638.29 -30,717.76
LAST 6M 167,920.74 50,623.85
LAST 12M 262,867.28 126,756.31

Ipca Laboratories Ltd Information

Stock PE (TTM)
64.37
Promoter Holding
46.3%
Book Value
242.3582
ROCE
11.59%
ROE
8.7%
Description
  • Ipca Laboratories Ltd is a pharmaceutical company based in India. On October 19, 1949, the company was incorporated in Mumbai under the name The Indian Pharmaceutical Combine Association Limited. The company was named Ipca laboratories Ltd in 1964, and then it was changed to Ipca Laboratories Private Limited. However, in 1988, it was again changed back to Ipca Laboratories Ltd.

    Ipca laboratories Ltd is listed on the Bombay Stock Exchange with the code 524494 and on the National Stock Exchange with the symbol IPCALAB. The company had a market capitalisation of Rs 22,016 crore on November 18, 2022.

    Ipca Laboratories Ltd manufactures over 350 formulations and 80 active pharmaceutical ingredients (APIs). It has 17 manufacturing units across India, and its products are exported to 100 countries. Some APIs that Ipca Laboratories Ltd manufactures are Atenolol, Chloroquine phosphate, Chlorthalidone, Furosemide, and Hydroxychloroquine sulfate. The company has introduced a number of medicine brands, such as Zerodo, Perinorm, Tenoric, Lumerax, and Folitrax, to name a few. The subsidiary companies of Ipca laboratories Ltd are Ipca Pharmaceuticals Inc, Ipca laboratories (UK) Ltd, and Tonira Exports Ltd.

    On November 17, 2022, Ipca Laboratories Ltd’s share price closed at Rs 867.80. The share prices of Ipca laboratories Ltd have risen by 52.29% over the past three years and fallen by 16.63% in the past 12 months. The share’s 52-week high was Rs 1,128.50, and the 52-week low was Rs 831.05 as of November 18, 2022.

    In the third quarter of 2022, the company’s revenue was Rs 1,601 crore, which is 0.95% more than the previous quarter. The company had the best quarter in September 2021, with a profit of Rs 250 crore. The profit in the September quarter of 2022 was Rs 144 crore.

    As of November 18, 2022, 46.29% of Ipca Laboratories Ltd’s shares are owned by the promoters, followed by mutual funds and foreign institutional investors with 29.71% and 10.55% company shares, respectively.

    Premchand Godha is the chairman and managing director of the company, Ajit Kumar Jain is the joint managing director, and Pranay Godha and Prashant Godha are executive directors.        

    Disclaimer: ICICI Securities Ltd. (I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is a Member of National Stock Exchange of India Ltd (Member Code: 07730), BSE Ltd (Member Code: 103) and Member of Multi Commodity Exchange of India Ltd.(Member Code:  56250) and having SEBI registration no. INZ000183631. Name of the Compliance officer (broking): Ms. Mamta Shetty, Contact number: 022-40701022, E-mail address: complianceofficer@icicisecurities.com. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Such representations are not indicative of future results. The securities quoted are exemplary and are not recommendatory. Investors should consult their financial advisers if in doubt about whether the product is suitable for them. The contents herein above are solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments or any other product. Investors should consult their financial advisers whether the product is suitable for them before taking any decision. The contents herein mentioned are solely for informational and educational purpose.

Registered Address

48 Kandivli Industrial Estate, Kandivli (West), Mumbai, Maharashtra, 400067

Tel : 91-22-66474444
Email : investors:ipca.com ; ipca:ipca.com
Website : http://www.ipca.com
Registrar

Link Intime India Pvt Ltd

AGM Date (Month) : Aug
Face Value Equity Shares : 1
Market Lot Equity Shares : 1
BSE Code : 524494
NSE Code : IPCALAB
Book Closure Date (Month) :
BSE Group : A
ISIN : INE571A01038

FAQ’s on Ipca Laboratories Ltd Shares

You can buy Ipca Laboratories Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Ipca Laboratories Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of May 27, 2024 02:19 PM the closing price of Ipca Laboratories Ltd was Rs.1,298.95.

Market capitalization or market cap is determined by multiplying the current market price of a company�s shares with the total number of shares outstanding. As of May 27, 2024 02:19 PM, the market cap of Ipca Laboratories Ltd stood at Rs. 32,954.88.

The latest PE ratio of Ipca Laboratories Ltd as of May 27, 2024 02:19 PM is 64.37

The latest PB ratio of Ipca Laboratories Ltd as of May 27, 2024 02:19 PM is 0.19

The 52-week high of Ipca Laboratories Ltd share price is Rs. 1,374.60 while the 52-week low is Rs. 675.45

According to analyst recommendations, Ipca Laboratories Ltd Share has a "Buy" rating for the long term.

Download App

Download Our App

Play Store App Store
market app